Clinical applications of mifepristone

Gynecological Endocrinology

Volumn 22, Issue 12, 2006, Pages 655-659

  Tang, Oi Shan ^a   Ho, Pak Chung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cervical priming; Emergency contraception; Medical abortion

Indexed keywords

GEMEPROST; GEMEPROSTZ; LEVONORGESTREL; MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN DERIVATIVE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EMERGENCY CONTRACEPTION; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; GYNECOLOGIC CANCER; HORMONAL REGULATION; HUMAN; INDUCED ABORTION; LOW DRUG DOSE; ORAL CONTRACEPTION; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; TREATMENT OUTCOME; UTERINE CERVIX DILATATION; UTERINE CERVIX RIPENING; UTERUS MYOMA;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ABORTION, SPONTANEOUS; CONTRACEPTIVE AGENTS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; MIFEPRISTONE; PREGNANCY;

EID: 33845606315     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590601005946     Document Type: Review

References (48)

1. Baird DT. Overview of abortion techniques. In: Baird DT, Grimes DA, Van Look PFA, editors. Modern methods of inducing abortion. Oxford: Blackwell Science; 1995. pp 25-38.
2. Fiala C, Gemzell-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception 2006;74:66-86.
3. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br J Obstet Gynaecol 2000;107:524-530.
4. El-Refaey H, Rajasekar D, Abdalia M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987.
5. Ashok PW, Penney GC, Flett GMM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13:2962-2965.
6. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost. Acta Obstet Gynaecol Scand 2001;80:447-451.
7. Kapp N, Borgatta L, Ellis SC, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. Contraception 2006;73:525-527.
8. World Health Organization. Lowering the doses of mifepristone and gemeprost for early abortion: a randomised controlled trial. Br J Obstet Gynaecol 2001;108:738-742.
9. Heikinheimo O, Kekkonen R. Dose-response relationship of RU 486. Ann Med 1993;25:71-76.
10. Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. J Am Med Assoc 2000;284:1948-1953.
11. Murthy AS, Crenin MD, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception 2005;71:333-336.
12. Fox MC, Crenin MD, Harwood B. Mifepristone and vaginal misoprostol on the same day for abortion from 50-63 days' gestation. Contraception 2002;66:225-229.
13. Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet 1998;352:542-543.
14. Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second trimester abortion. Obstet Gynecol 1997;90:896-900.
15. El-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester. A radnomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). Hum Reprod 1993;8:1744-1746.
16. Ho PC, Chan YF, Lau W. Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomized comparative trial. Contraception 1996;53:281-283.
17. Wong KS, Ngai SW, Chan KS, Tang CH, Ho PC. Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double-blind placebo-controlled trial. Contraception 1996;54:23-25.
18. Wong KS, Ngai CSW, Wong AY, Tang LCH, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998;58:207-210.
19. Rodger MW, Baird DT. Pretreatment with mifepristone reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Osbtet Gynaecol 1990;97:41-45.
20. Ho PC, Ma HK. Termination of second trimester pregnancy with sulprostone and mifepristone: a randomized double-blind placebo controlled trial. Contraception 1993;47: 123-129.
21. Webster D, Penney G, Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynaecol 1996;103:706-709.
22. Heikinheimo O, Suhonen S, Haukkamaa M. One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 2003;8:236-239.
23. Johnson N. Intracervical tents: usage and mode of action. Obstet Gynecol Surv 1989;44:410-420.
24. Ngai SW, Tang OS, Lao T, Ho PC, Ma HK. Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancy. Hum Reprod 1995;10: 1220-1222.
25. Ngai SW, Au Yeung KC, Lao T, Ho PC. Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomized study. Br J Obstet Gynaecol 1996;103:1120-1123.
26. El-Refaey H, Calder L, Wheatley DN, Templeton A. Cervical priming with prostaglandin E1 analgues, misoprostol and gemeprost. Lancet 1994;343:1207-1209.
27. Henry A, Haukkamaa M. Comparison of vaginal misoprostol and gemeprost as pre-treatment in first trimester pregnancy interruption. Br J Obstet Gynaecol 1999;106: 540-543.
28. Clark K, Ji H, Feltovich H, Janowski J, Carroll C, Chien E. Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events. Am J Obstet Gynecol 2006;194: 1391-1398.
29. Ngai SW, Au Yeung KC, Lao T, Ho PC. Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestation. Contraception 1995;51:347-350.
30. Ngai SW, Chan YM, Tang OS, Ho PC. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod 1999;14: 2139-2142.
31. Lelaidier C, Baton-Saint-Mleux C, Fernandez H, Bourget P, Frydman R. Mifepristone (RU 486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum Reprod 1993;8:492-495.
32. Wagaarachchi PT, Ashok PW, Narvekar N, Smith NC, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod 2001;16:1849-1853.
33. Gronlund A, Gronlund L, Clevin L, Andersen B, Palmgren N, Lidegaard O. Management of missed abortion: comparison of medical treatment with either mifepristone+ misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand 2002;81:1060-1065.
34. Webb AMC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU 486) in oral postcoital contraception. Br Med J 1992;305:927-931.
35. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-1044.
36. Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 1999;353: 697-702.
37. World Health Organization Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352: 428-433.
38. von Hertzen H, Piaggio G, Ding J. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360: 1803-1810.
39. Brown A, Cheng L, Lin S, Baird DT. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double blind randomized controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70.
40. Baird DT, Brown A, Critchley HOD, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68.
41. Baird DT, Brown A, Cheng L, Lin S, Narvekar N, Critchley HOD, Williams AR. Mifepristone: a novel estrogen-free daily contraceptive pill. Steroids 2003;68:1099-1105.
42. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8: 870-873.
43. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1996;14: 2709-2712.
44. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-866.
45. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178: 1151-1156.
46. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU 486: dose-response effect. Fertil Steril 1995;64:187-190.
47. Rocereto TF, Saul HM, Aikins JA, Paulson J. Phase II study of mifepristone (RU 486) in refractory ovarian cancer. Gynecol Oncol 2000;77:429-432.
48. DeBattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab 2006;17:117-121.